Although Trop-2 expression was identified as a favorable prognostic factor, its broad expression suggests that sacituzumab govitec may be a potential therapeutic option in a wide spectrum of patients with UTUC. This evidence concerns the gene TACSTD2 and renal pelvis/ureter urothelial carcinoma.